Medical Oncology Update

Friday, August 28, 2026
St Louis, Missouri

A CME/MOC-Accredited Interactive Grand Rounds Series

Access the slides, CME evaluation, and optional ABIM MOC post-test for the Grand Rounds activity you attended by using the corresponding links below.

Note: Please log in to our website before clicking on your session evaluation link.
If you don’t have an account, you can create one here. It’s free.

Hormone Receptor (HR)-Positive Localized Breast Cancer — Erica Stringer-Reasor, MD

  • Risk Assessment and Genomic Assays in the Management of HR-Positive, HER2-Negative Localized Breast Cancer
  • Adjuvant CDK4/6 Inhibitors for High-Risk HR-Positive, HER2-Negative Localized Breast Cancer
  • Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy

Diffuse Large B-Cell Lymphoma (DLBCL) — Gilles Salles, MD, PhD

  • Selection of First-Line Therapy for Patients with DLBCL
  • Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL
  • Evidence-Based Incorporation of Antibody-Drug Conjugates into the Management of R/R DLBCL